ESMO 2021: PARPi data and their role in mono/combination therapies
ESMO 2021: PARPi data and their role in mono/combination therapies
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC
ESMO 2021: Breast cancer roundup
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer
Welcome to APCCC 2021
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
ESMO 2021 Roundup
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma
OncoAlert and ecancer - ESMO 2021 Day 5